OTR Global has a Positive read on Tandem Diabetes (TNDM) and Insulet (PODD) after interviews with U.S. endocrinology practitioners that showed new insulin pump start growth has remained “strong” and is expected to continue during 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $50 from $57 at Citi
- Morgan Stanley upgrades ‘too cheap’ Tandem Diabetes to Overweight
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays
- Tandem Diabetes price target lowered to $40 from $43 at UBS